Reduced-intensity conditioning HCT in patients 50 years and older with acute myelogenous leukemia (AML) in complete remission has similar outcomes using sibling donors, unrelated donors, and cord blood units, with adjusted three-year survival of 55%, 45%, and 43%, respectively (p=0.26). Three-year cumulative incidences of transplant-related mortality (TRM) were 18%, 14%, and 24%, respectively (p=0.22). In multivariate analysis, only poor-risk cytogenetics was associated with relapse (hazard ratio [HR], 1.7 [95% confidence interval, 1.0 to 3.0], p=0.04) and worse leukemia-free survival (HR, 1.6 [95% confidence interval, 1.0 to 2.5], p=0.03), but donor choice had no significant impact on survival (p=0.73).
Similar Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts in AML
Jul 2013